1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel

Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel

The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The five branded anti-TNF antibodies Humira, Remicade, Enbrel, Simponi and Cimzia together achieved global sales of US$ 34.4 bln (+12.9%) in the year 2014. While the first biosimilars of Humira, Remicade and Enbrel are already marketed in less regulated countries such as India and China, it is only in February of 2015 that a biosimilar TNF antibody has been launched in the European Union. The Marketing Authorization Applications of further two biosimilar TNF antibodies have been just been submitted to the European Medicines Agency and the clinical pipeline of is rather full.

The report includes a compilation of currently active R&D projects of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: TNF Antibodies 2015- Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Competitor Analysis: TNF Antibodies 2015- Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Table of Contents:
1. TNF Antibodies 2015 - Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
-           Humira Sales and Pipeline
-           Remicade Sales and Pipeline
-           Enbrel Sales and Pipeline
-           Simponi Sales and Pipeline
-           Cimzia Sales and Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
-           Humira Biosimilar Antibody Pipeline
-           Remicade Biosimilar Antibody Pipeline
-           Enbrel Biosimilar Antibody Pipeline
-           Cimzia Biosimilar Antibody Pipeline
2.  Corporate TNF Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.